drugset / Trial / NCT00955396

Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure

NCT00955396

Phase 1 Completed 60 enrolled Biogen
RandomizedCrossoverDouble-blindOther

Summary

In this study the investigators will determine whether there is any effect of GSK1014802 on ambulatory blood pressure. This will be a randomized, double-blind, placebo-controlled, repeat dose, 2 period cross-over study conducted in healthy male and female subjects. Approximately 60 subjects will be randomised to receive GSK1014802 400 mg bid and placebo for 36 days with at least 1 week between treatment sessions. A follow-up will occur 7-14 days after the last dose.

Timeline

Start
2009-07-31
Primary completion
2009-12-31
Completion
2009-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Vixotrigine Small molecule 400 mg

Indications

No indication recorded.